Pharmaceutical News

RSS

New study shows that chronic narcotic use more prevalent in children with IBD

Chronic narcotic use is more than twice as prevalent in children with inflammatory bowel disease (IBD), compared with children without this disease, according to a new study1 published in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.

10 Feb 2015

Combination therapies may overcome resistance to targeted cancer drugs

A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers.

10 Feb 2015

FDA accepts NDA filing for Inspirion Delivery Technologies' investigational drug, MorphaBond ER

Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.

10 Feb 2015

Cohera Medical gets FDA approval to distribute TissuGlu Surgical Adhesive in US

Cohera Medical, Inc.®, a leading innovator and developer of surgical adhesives and sealants, announced today that the U.S. Food and Drug Administration (FDA) has approved its TissuGlu® Surgical Adhesive.

9 Feb 2015

New AGA guideline provides guidance to prevent HBV reactivation

Long-term immunosuppressive therapy can cause the hepatitis B virus (HBV) to become active, even in patients who are not aware that they are infected with the virus. A new guideline from the American Gastroenterological Association provides guidance to physicians and patients who use immunosuppressive agents for the treatment of a variety of disorders, including gastrointestinal, dermatologic, neurologic and rheumatologic, among others.

9 Feb 2015

Study explores effects of medical marijuana in children and teens with ASD, ADHD

As medical marijuana becomes increasingly accepted, there is growing interest in its use for children and adolescents with developmental and behavioral problems such as autism spectrum disorders (ASD) and attention-deficit/hyperactivity disorder (ADHD), according to a review in the February Journal of Developmental & Behavioral Pediatrics, the official journal of the Society for Developmental and Behavioral Pediatrics.

9 Feb 2015

Salicylates drugs reduce proliferation, viability of cultured vestibular schwannoma cells

Researchers from Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology's Program in Speech and Hearing Bioscience and Technology have demonstrated that salicylates, a class of non-steroidal inflammatory drugs (NSAIDs), reduced the proliferation and viability of cultured vestibular schwannoma cells that cause a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.

9 Feb 2015

Confidence in government may play key role in public's willingness to take swine flu vaccine

A new study suggests that confidence in government may play a key role in the public's willingness to get at least some vaccine

9 Feb 2015

Added benefit of lurasidone drug not proven for schizophrenia

The drug lurasidone (trade name Latuda) has been available since November 2014 for the treatment of adults with schizophrenia. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.

8 Feb 2015

American Osteopathic Association reiterates support for CDC vaccination protocols

Amid continuing outbreaks of preventable illnesses, the American Osteopathic Association reiterated its support for CDC vaccination protocols and cited the importance of a fully vaccinated population on the public health of the nation.

7 Feb 2015

Chinese researchers achieve major breakthrough in nano-carrier drugs for pancreatic cancer

At the "Symposium on the Application of Genetic Testing in Individualized Diagnosis and Treatment of Tumor" recently held in Tianjin, the research team led by Professor Hao Jihui of the Pancreas Oncology Department of Tianjin Medical University Cancer Hospital announced that they had achieved a major breakthrough in the field of nano-carrier drugs for pancreatic cancer.

6 Feb 2015

Chemotherapy or immunosuppressive treatment may reactivate HBV

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, "Reactivation of Hepatitis B," and published in Hepatology, a journal of the American Association for the Study of Liver Diseases.

6 Feb 2015

Breakthrough therapies for blood cancers may provide reasonable value for money spent

Amid the growing debate about the high price of powerful new drugs in the United States, a recent analysis suggests that breakthrough therapies for blood cancers may, in many cases and with some important caveats, provide reasonable value for money spent.

6 Feb 2015

Breakthrough blood cancer therapies may provide reasonable value for money spent

6 Feb 2015

MIT engineers discover way to grow liver-like cells to test potential malaria drugs

In 2008, the World Health Organization announced a global effort to eradicate malaria, which kills about 800,000 people every year. As part of that goal, scientists are trying to develop new drugs that target the malaria parasite during the stage when it infects the human liver, which is crucial because some strains of malaria can lie dormant in the liver for several years before flaring up.

6 Feb 2015

New report explores measures to address shortages of lifesaving medicines

As shortages of lifesaving medicines, including antibiotics, chemotherapy, and cardiovascular drugs continue to plague the United States, a group of health care organizations released a report exploring measures that should be considered to address this ongoing issue. The report summarizes manufacturing, regulatory, and economic issues related to drug shortages, as well as potential solutions that were considered at a 2014 Summit attended by 22 stakeholder groups, including health care professionals and other non-profit organizations, industry, public interest, and government agencies.

6 Feb 2015

G1 Therapeutics receives $33 million in Series B funding to develop effective treatments for cancer

An RTP-based pharmaceutical company with roots at the University of North Carolina at Chapel Hill has received $33 million in Series B venture capital funding to develop more effective and less toxic methods to treat patients with cancer.

6 Feb 2015

Isis receives $10 million from Biogen Idec to begin IND-supporting studies of ISIS-BIIB4 Rx

Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec for initiating the investigational new drug (IND)-supporting studies of ISIS-BIIB4 Rx.

5 Feb 2015

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapies addressing high-unmet medical needs, today announced the closing of its previously disclosed exclusive global license agreement for the therapeutic use of Samcyprone with Hapten Pharmaceuticals, LLC.

5 Feb 2015

Study: 45% of RTI patients inappropriately prescribed antibiotics in outpatient settings

A new study found 45 percent of patients with respiratory tract infections (RTIs) were inappropriately prescribed antibiotics in an outpatient practice of general internal medicine and family medicine.

5 Feb 2015

Pharmaceutical News

New study shows that chronic narcotic use more prevalent in children with IBD

Combination therapies may overcome resistance to targeted cancer drugs

FDA accepts NDA filing for Inspirion Delivery Technologies' investigational drug, MorphaBond ER

Cohera Medical gets FDA approval to distribute TissuGlu Surgical Adhesive in US

New AGA guideline provides guidance to prevent HBV reactivation

Study explores effects of medical marijuana in children and teens with ASD, ADHD

Salicylates drugs reduce proliferation, viability of cultured vestibular schwannoma cells

Confidence in government may play key role in public's willingness to take swine flu vaccine

Added benefit of lurasidone drug not proven for schizophrenia

American Osteopathic Association reiterates support for CDC vaccination protocols

Chinese researchers achieve major breakthrough in nano-carrier drugs for pancreatic cancer

Chemotherapy or immunosuppressive treatment may reactivate HBV

Breakthrough therapies for blood cancers may provide reasonable value for money spent

Breakthrough blood cancer therapies may provide reasonable value for money spent

MIT engineers discover way to grow liver-like cells to test potential malaria drugs

New report explores measures to address shortages of lifesaving medicines

G1 Therapeutics receives $33 million in Series B funding to develop effective treatments for cancer

Isis receives $10 million from Biogen Idec to begin IND-supporting studies of ISIS-BIIB4 Rx

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

Study: 45% of RTI patients inappropriately prescribed antibiotics in outpatient settings

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News